Sign Out
Pregnancy: As with other drugs known to inhibit prostaglandin synthesis, use of etoricoxib should be avoided in late pregnancy because it may cause premature closure of the ductus arteriosus. There are no adequate and well-controlled studies in pregnant women. Etoricoxib should be used during the first two trimesters of pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: Etoricoxib is excreted in the milk of lactating rats. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the possible adverse effects of drugs that inhibit prostaglandin synthesis on nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
